The Peanut Allergy Treatment Market is likely to grow on a robust note in the next decade. The next decade would be seeing the integration of telehealth services with the physical ones that exist at the moment. Urgent care and primary care are bound to be accessed through virtual visits, along with improvement in collaboration with the clinics, dialysis centres, long-term care facilities, and mental health services. This shifting is to be witnessed in the healthcare vertical shortly.
Peanut allergy is the most common of childhood food allergies. Around 2.5% of children suffered from peanut allergy in the United States. Peanut allergy can cause several allergic reactions including anaphylaxis. There is no approved treatment available for the peanut allergy, only the experimental drugs are used for the peanut allergy treatment.But manufacturers and researcher are studying the use of the immunotherapy drugs for the of peanuts allergy treatment. Immunotherapy drugs are not FDA approved till now. FDA is expected to approve one or more than one peanut allergy immunotherapy products for peanut allergy treatment.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/28831
Companies such as DBV Technologies, Aimmune Therapeutics, Prota Therapeutics Pty Ltd., Camallergy are conducting clinical trials for the development of peanut allergy treatment products. DBV technologies immunotherapy product ‘Viaskin Peanut’ will be most likely to be first peanut allergy treatment product in the market. Viaskin Peanut is skin or a dermal patch containing 250 microgram of peanut protein drugs.
Peanut allergy treatment market expected to grow with a double-digit growth rate as the expected launch of the new products in the market. These products will gain higher demand in the market as unavailability of peanut allergy treatment medicines.
Peanut allergy treatment market expected to gain significant growth rate over the forecast period as increasing number of clinics visit for allergy treatment. Increasing number of research and development for the launch of immunotherapy products expected to boost up growth opportunity for peanut allergy treatment market. Peanut allergy treatment market will spur over the forecast period as increasing investments, scientific developments, and commercial activities.
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/28831
Market Segmentation
| Drug Type |
|
| Route of Administration |
|
| Distribution Channel |
|
Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com
Regionally, the global peanut allergy treatment market is segmented into five key regions viz. North America, Latin America, Europe, Middle East & Africa and the Asia Pacific. North America is expected to contribute a major revenue share in the global peanut allergy treatment market owing to the high prevalence of peanut allergy.North America and Europe expected to gain most of the share in the peanut allergy treatment market as increasing prevalence of peanut allergy in western countries. Peanut allergy treatment market in the Asia-Pacific region is expected to witness significant growth rate in the coming years due to the growing number of allergy testing and increasing healthcare spending.Some of the players operating in the global peanut allergy treatment market are Mylan Inc., Sanofi SA, Pfizer Inc., kaleo, Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Inc., DBV Technologies, Aimmune Therapeutics, Prota Therapeutics Pty Ltd., and others.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/28831
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com